Will India's APIs Incentive Scheme Galvanize Local Firms?
Aims To Improve Self-Sufficiency
Executive Summary
India shapes new production-linked incentives scheme for critical APIs to ensure self-reliance and cut massive dependence on imports from China, but much will depend on actual implementation, including timely clearances. Pharma will also need to 'walk the talk' alongside.
You may also be interested in...
COVID-19 Lesson: India Earmarks $1.3bn To Reduce Dependence On China
In a bid to ensure long-term medicines security, the Indian government has earmarked $1.32bn to promote domestic production of 53 APIs, including lopinavir and ritonavir currently being evaluated to treat COVID-19 cases, as well as antibiotics, for which India is highly dependent on China.
China API Juggernaut Rolls On But Can India Recoup?
Report: India’s huge dependence on Chinese active pharmaceutical ingredients (APIs), including in high disease burden areas, poses heightened risks to its health security and requires “urgent interventions.”
Glenmark Divests API Company, Setting Out On Distinct Journeys
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”